Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)

Jian Pei, Pei Li, Yun H. Gao, Bao G. Tian, Da Y. Wang, Yu Zheng, Li Y. Liu, Zhi Y. Zhang, Si S. Huang, Min Wen, Xiangdong Xu, Lei XiaJournal of Neuro-Oncology 2023 · DOI

Abstract

This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.

Introduction

Meningiomas are the most prevalent primary intracranial tumors. While the majority are benign and well-demarcated from the surrounding brain tissue, a subset exhibits brain invasion (BI). The presence of BI classifies a tumor as WHO Grade 2 or 3, indicating a more aggressive clinical course with higher recurrence rates and poorer prognosis. Currently, the identification of BI relies on surgical observation and histopathological examination, both of which are subject to sampling bias and inter-observer variability. There is a pressing need for objective molecular biomarkers to accurately diagnose invasive meningiomas and guide personalized treatment.

Methods

The study utilized a proteomic approach to identify differential protein expression between invasive and non-invasive meningiomas.

Patient Cohort and Sample Collection

Tissue samples were collected from 42 patients at TangShan GongRen Hospital (2005–2021), comprising 21 brain-invasive (Grade III) and 21 non-invasive (Grade I) meningiomas. Strict inclusion criteria, including MRI and intraoperative findings, were used to define the invasive group.

Proteomic Analysis

Proteins were extracted and analyzed using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Raw data were processed with MaxQuant software and searched against the UniProt database (2013.08 release) for protein identification and quantification.

Validation

Immunohistochemistry (IHC) was performed on tissue sections to validate the expression levels and localization of the candidate protein, canstatin, within the tumor microenvironment.

Results

The LC-MS/MS analysis identified a total of 6,498 unique proteins. Differential expression analysis revealed significant proteomic shifts between the two groups.

Volcano plot showing differentially expressed proteins between invasive and non-invasive meningiomas.

Canstatin Expression

Canstatin, a 24 kDa fragment of the α2-chain of Type IV collagen, was identified as a key differentially expressed protein. It was found to be 2.1-fold more abundant in non-invasive tumors compared to invasive ones. As an endogenous angiogenesis inhibitor, canstatin typically suppresses endothelial cell proliferation and induces apoptosis. Its depletion in invasive tumors suggests a loss of this inhibitory "brake," potentially facilitating basement membrane degradation and tumor cell migration into the brain parenchyma.

IHC Validation

IHC staining confirmed the proteomic findings. Non-invasive tumors exhibited significantly stronger canstatin staining (mean score 2.35) compared to invasive tumors (mean score 1.75; $p = 0.0132$). Additionally, the invasive group showed a markedly higher Ki-67 proliferation index (27% vs. 2.32% in non-invasive tumors), underscoring their aggressive nature.

Immunohistochemical staining of meningioma tissues showing variations in canstatin expression.

Discussion

This study identifies canstatin as a potential molecular marker for brain invasion in meningiomas. The significant down-regulation of this matrikine in invasive tumors provides insight into the mechanisms of tumor progression and offers an objective tool for pathological grading.

While these results are promising, the study's sample size is relatively small, and further validation in larger, multi-center cohorts is necessary. Future research should also include Grade II tumors to determine canstatin's utility in clinically ambiguous cases. Furthermore, functional in vivo studies are required to confirm whether canstatin supplementation could serve as a therapeutic strategy to inhibit brain invasion. As a naturally occurring protein fragment, canstatin represents a compelling target for developing novel, targeted therapies with potentially fewer side effects than conventional treatments.

Summary updated

Abstract

This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.
BibTeX
@article{pei2023type,
  author = {Jian Pei and Pei Li and Yun H. Gao and Bao G. Tian and Da Y. Wang and Yu Zheng and Li Y. Liu and Zhi Y. Zhang and Si S. Huang and Min Wen and Xiangdong Xu and Lei Xia},
  title = {{Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)}},
  journal = {Journal of Neuro-Oncology},
  year = {2023},
  doi = {10.1007/s11060-023-04256-z},
}
Figure